Subscribe To

Price Alert Latest News Economic Calendar News

DRIO / DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common comorbidity conditions, including diabetes, weight loss, hypertension, musculoskeletal and behavioral health, across six domains: timing, tone, channel, content, frequency and intervention. Read More

Demo Live Account See Partner Details

Content Topics

Dariohealth

Ai

Powered

Digital

Therapeutics

Play

Ai powered

Stock

DRIO

Posted: Jun 13 2023, 08:36

Author Name: MarketBeat

DRIO News

By Seeking Alpha
October 3, 2023

DarioHealth Disappoints, But A Better Future Is Ahead

DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected

By MarketBeat
June 13, 2023

DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for ch

By Seeking Alpha
May 11, 2023

DarioHealth Corp. (DRIO) Q1 2023 Earnings Call Transcript

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Inves

By Seeking Alpha
March 9, 2023

DarioHealth Corp. (DRIO) Q4 2022 Results Conference Call

DarioHealth Corp. (NASDAQ:DRIO ) Q4 2022 Results Conference Call March 9, 2023 8:30 PM ET Company Participants Glenn Garmont - Investor Relations Erez

By Seeking Alpha
February 2, 2023

DarioHealth: January Rally Looks To Be Exhausting (Technical Analysis)

DarioHealth rallied off a low in December and since raced to new highs. Market generated data suggests the rally could extend over the coming weeks to

By Seeking Alpha
November 17, 2022

DarioHealth: Market Sentiment Shift Post Q3 Numbers, Revise To Speculative Buy

We've revised our rating on DarioHealth to a buy, with consideration to tactical allocation for equity portfolios. DRIO's Q3 numbers came in strong wi

By Benzinga
June 15, 2022

Dario Health (DRIO) Poised To Inflect Upon Full Launch of National Health Plan

Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after r

By Seeking Alpha
May 12, 2022

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2022 Results - Earnings Call Transcript

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.